Trials / Completed
CompletedNCT04392960
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Molecular, Magnetic Resonance, and Echocardiographic Imaging Combined With Biomarkers of Cardiac and Clonal Disease to Predict Survival and Assess Response to Therapy in Cardiac AL Amyloidosis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]Florbetaben | Patients will undergo on the same day: * 18F-florbetaben PET-CT scans. The dose to be injected intravenously (6 second/mL) will be 370 MBq (for a 70 Kg patient); * standard assessment of clonal and organ disease; * echocardiography; * cardiac magnetic resonance. All the patients will undergo those evaluations at baseline and 6 months after treatment initiation. |
Timeline
- Start date
- 2020-07-22
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
- First posted
- 2020-05-19
- Last updated
- 2026-04-16
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT04392960. Inclusion in this directory is not an endorsement.